Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan.

The long-term efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC) have not been well-evaluated. Here, we reviewed the long-term durability and safety of IFX in our single center pediatric cohort with UC. This retrospective study included 20 children with UC who were administered IFX. For induction, 5 mg/kg IFX was administered at weeks 0, 2, and 6, followed by every 8 weeks for maintenance. The dose and interval of IFX were adjusted depending on clinical decisions. Corticosteroid (CS)-free remission without dose escalation (DE) occurred in 30% and 25% of patients at weeks 30 and 54, respectively. Patients who achieved CS-free remission without DE at week 30 sustained long-term IFX treatment without colectomy. However, one-third of the patients discontinued IFX treatment because of a primary nonresponse, and one-third experienced secondary loss of response (sLOR). IFX durability was higher in patients administered IFX plus azathioprine for >6 months. Four of five patients with very early onset UC had a primary nonresponse. Infusion reactions (IRs) occurred in 10 patients, resulting in discontinuation of IFX in four of these patients. No severe opportunistic infections occurred, except in one patient who developed acute focal bacterial nephritis. Three patients developed psoriasis-like lesions. IFX is relatively safe and effective for children with UC. Clinical remission at week 30 was associated with long-term durability of colectomy-free IFX treatment. However, approximately two-thirds of the patients were unable to continue IFX therapy because of primary nonresponse, sLOR, IRs, and other side effects.

Informations de copyright

Copyright © 2021 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.

Déclaration de conflit d'intérêts

Conflict of Interest: Hirotaka Shimizu received honoraria from Mitsubishi Tanabe Pharma Corporation and Nippon Kayaku Co., Ltd., and a grant from Nippon Kayaku Co., Ltd. Katsuhiro Arai received honoraria from Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., AbbVie GK, and Janssen Pharmaceutical K.K., and a grant from Nippon Kayaku Co., Ltd. For the remaining authors, none was declared.